Altacor to evaluate lead compound from Proximagen's 5HT2c programme for glaucoma
25 November 2011
Nancy Faigen
Please Login to read the full article.
25 November 2011
Nancy Faigen
Nancy.faigen@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Bausch + Lomb trumps failed Valeant bid for ISTA with $500m deal
- Eleven Biotherapeutics: closer to the clinic with a protein for topical delivery in dry eye
- Heart, liver risks spark US FDA concerns with Astellas OAB drug
- ROCK on, ROCK off: Amakem gets €18 million to address rho kinase side-effect problem
COMMENT
Other Informa Comment
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
